Churg-Strauss syndrome risk factors: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Churg-Strauss syndrome}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References==...")
 
No edit summary
 
(21 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Churg-Strauss syndrome}}
{{Churg-Strauss syndrome}}
{{CMG}}; {{AE}}{{CK}}
==Overview==
There are no established risk factors for [[eosinophilic granulomatosis with polyangiitis]]. However, certain environmental agents including various [[Allergen|allergens]], [[Infection|infections]], [[Desensitization (medicine)|desensitization]], [[vaccination]], and [[genetics]] may act as triggering agents. Those triggers may be responsible for the [[Inflammation|inflammatory response]] with [[Eosinophil granulocyte|eosinophils]] and [[Lymphocyte|lymphocytes]] and [[Macrophage|macrophages]].


Please help WikiDoc by adding content hereIt's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
==Risk Factors==
*Various environmental agents including various [[Allergen|allergens]], [[Infection|infections]], [[Desensitization (medicine)|desensitization]], [[vaccination]], and [[genetics]] may act as triggering agents. These triggers may be responsible for the [[Inflammation|inflammatory response]] with [[Eosinophil granulocyte|eosinophils]] and [[Lymphocyte|lymphocytes]] leading to [[vasculitis]] and [[necrosis]].
==Common Risk Factors==
Common [[Risk factor|risk factors]] in the development of [[eosinophilic granulomatosis with polyangiitis]] may be various [[Allergen|allergens]], [[Infection|infections]], [[Genetics|genetic factors]], and desensitization to [[:Category:Drugs|drugs]] and [[Vaccination|vaccinations.]]
*Genetic determinants:<ref name="pmid17763415">{{cite journal |vauthors=Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM |title=HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome |journal=Arthritis Rheum. |volume=56 |issue=9 |pages=3159–66 |date=September 2007 |pmid=17763415 |doi=10.1002/art.22834 |url=}}</ref><ref name="pmid18512809">{{cite journal |vauthors=Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT |title=Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis |journal=Arthritis Rheum. |volume=58 |issue=6 |pages=1839–48 |date=June 2008 |pmid=18512809 |doi=10.1002/art.23496 |url=}}</ref>
**[[Human leukocyte antigen|HLA]]-DRB1*04 AND *07
**[[HLA-DRB4]]
**[[Interleukin 10]] gene [[Single nucleotide polymorphism|single nucleotide polymorphisms]]
*[[Allergy|Allergic agents]]
*[[Infection|Infections]]
*[[Vaccination]]
*Exposure to [[Silicon dioxide|silica]]<ref name="pmid23820041">{{cite journal |vauthors=Gómez-Puerta JA, Gedmintas L, Costenbader KH |title=The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis |journal=Autoimmun Rev |volume=12 |issue=12 |pages=1129–35 |date=October 2013 |pmid=23820041 |pmc=4086751 |doi=10.1016/j.autrev.2013.06.016 |url=}}</ref>
*[[:Category:Drugs|Drugs]]:<ref name="pmid18549941">{{cite journal |vauthors=Puéchal X, Rivereau P, Vinchon F |title=Churg-Strauss syndrome associated with omalizumab |journal=Eur. J. Intern. Med. |volume=19 |issue=5 |pages=364–6 |date=July 2008 |pmid=18549941 |doi=10.1016/j.ejim.2007.09.001 |url=}}</ref><ref name="pmid8834352">{{cite journal |vauthors=Orriols R, Muñoz X, Ferrer J, Huget P, Morell F |title=Cocaine-induced Churg-Strauss vasculitis |journal=Eur. Respir. J. |volume=9 |issue=1 |pages=175–7 |date=January 1996 |pmid=8834352 |doi= |url=}}</ref>
**[[Leukotriene antagonist|Leukotriene receptor antagonists]]/ Leukotriene modifying agents (eg, [[montelukast]], [[zafirlukast]])
**Anti-IgE antibody (eg, [[omalizumab]])
**[[Cocaine]]
**Inhaled [[glucocorticoids]]
**[[Mesalazine]]
**[[Propylthiouracil]]
**[[Methimazole]]
**[[Macrolide|Macrolides]]


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Autoimmune diseases]]
[[Category:Rheumatology]]
[[Category:Needs content]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]

Latest revision as of 17:52, 12 April 2018

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome risk factors

CDC on Churg-Strauss syndrome risk factors

Churg-Strauss syndrome risk factors in the news

Blogs on Churg-Strauss syndrome risk factors

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

There are no established risk factors for eosinophilic granulomatosis with polyangiitis. However, certain environmental agents including various allergens, infections, desensitization, vaccination, and genetics may act as triggering agents. Those triggers may be responsible for the inflammatory response with eosinophils and lymphocytes and macrophages.

Risk Factors

Common Risk Factors

Common risk factors in the development of eosinophilic granulomatosis with polyangiitis may be various allergens, infections, genetic factors, and desensitization to drugs and vaccinations.

References

  1. Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM (September 2007). "HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome". Arthritis Rheum. 56 (9): 3159–66. doi:10.1002/art.22834. PMID 17763415.
  2. Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT (June 2008). "Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis". Arthritis Rheum. 58 (6): 1839–48. doi:10.1002/art.23496. PMID 18512809.
  3. Gómez-Puerta JA, Gedmintas L, Costenbader KH (October 2013). "The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis". Autoimmun Rev. 12 (12): 1129–35. doi:10.1016/j.autrev.2013.06.016. PMC 4086751. PMID 23820041.
  4. Puéchal X, Rivereau P, Vinchon F (July 2008). "Churg-Strauss syndrome associated with omalizumab". Eur. J. Intern. Med. 19 (5): 364–6. doi:10.1016/j.ejim.2007.09.001. PMID 18549941.
  5. Orriols R, Muñoz X, Ferrer J, Huget P, Morell F (January 1996). "Cocaine-induced Churg-Strauss vasculitis". Eur. Respir. J. 9 (1): 175–7. PMID 8834352.

Template:WH Template:WS